<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039208</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-05011</org_study_id>
    <secondary_id>EORTC-05011</secondary_id>
    <nct_id>NCT00039208</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Colorectal Cancer</brief_title>
  <official_title>Time Finding Study of Chronomodulated Irinotecan, 5 Fluorouracil, Leucovorin and Oxaliplatin as First or Second Chemotherapy Line Against Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Giving drugs at the time of day that allows for the best drug
      response may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor
      cells.

      PURPOSE: Randomized phase II trial to determine the best time to give irinotecan combined
      with fluorouracil, leucovorin, and oxaliplatin in treating patients who have colorectal
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the role of peak delivery time on the tolerability of irinotecan when
           administered with chronomodulated fluorouracil, leucovorin calcium, and oxaliplatin as
           first- or second-line therapy in patients with locoregional or metastatic colorectal
           cancer.

        -  Determine the antitumor activity of this regimen.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, WHO performance status (0-1 vs 2), and line of treatment (first vs
      second). Patients are randomized to receive irinotecan at 1 of 6 different times of the day.

      Patients receive irinotecan IV over 6 hours on day 1 and fluorouracil IV and leucovorin
      calcium IV over 11 hours followed by oxaliplatin IV over 11 hours on days 2-5. Courses repeat
      every 21 days in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 4 weeks until disease progression and then every 8 weeks
      thereafter.

      PROJECTED ACCRUAL: A maximum of 186 patients (31 per irinotecan administration time) will be
      accrued for this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak delivery time for CPT11 tolerability over the first 3 courses of treatment in patients who started therapy, excluding those who stopped prior to course 3 for reasons other than toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak delivery time for CPT11 activity over the first 3 courses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak delivery time for CPT11 tolerability and efficacy over the first 6 courses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe toxic events assessed by CTC v2.0 after each course of chemotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed colorectal cancer

          -  Unresectable metastatic or locoregional disease

          -  At least 1 measurable lesion outside a previously irradiated area or an area treated
             with physical devices (e.g., cryotherapy, laser, or thermoablation)

          -  No prior enrollment in EORTC-05963

          -  No symptomatic brain metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Neutrophil count greater than 2,000/mm^3

          -  Platelet count at least 90,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)

        Renal:

          -  Creatinine no greater than 1.5 times ULN

          -  No uncontrolled hypercalcemia

        Cardiovascular:

          -  No overt cardiac disease

        Pulmonary:

          -  No severe respiratory illness

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Male patients must use effective barrier contraception during and for up to 6 months
             after study

          -  No baseline diarrhea greater than grade I (must have less than 4 stools per 24 hours)

          -  No prior grade III or IV toxicity related to irinotecan

          -  No sensory or motor neuropathy with functional impairment

          -  No prior hypersensitivity to any study drug

          -  No other primary tumor except basal cell skin cancer or carcinoma in situ of the
             cervix

          -  No uncontrolled infectious or chronic disease

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent prophylactic growth factor therapy

        Chemotherapy:

          -  At least 1 month since prior chemotherapy

          -  No prior irinotecan, fluorouracil, leucovorin calcium, and oxaliplatin as combination
             therapy

          -  Other prior therapy containing irinotecan and/or oxaliplatin allowed

          -  No more than 1 prior chemotherapy regimen for metastatic or locoregional disease

          -  Adjuvant chemotherapy considered first-line therapy if tumor relapsed within 6 months
             of completion of therapy

        Endocrine therapy:

          -  No concurrent corticosteroids except for emergencies

        Radiotherapy:

          -  See Disease Characteristics

          -  Palliative radiotherapy for bone lesion allowed except for disease progression

        Surgery:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Garufi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituti Fisioterapici Ospitalieri - Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Notre Dame - Reine Fabiola</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Joseph</name>
      <address>
        <city>Liege</city>
        <zip>B 4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita G.D'Annunzio Di Chieti</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Carlo Borromeo</name>
      <address>
        <city>Milano (Milan)</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale S. Luigi at University of Torino</name>
      <address>
        <city>Orbassano, (Torino)</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <zip>I-27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Oncologico Regionale</name>
      <address>
        <city>RIONERO in VULTURE</city>
        <zip>I-58028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Beato Matteo</name>
      <address>
        <city>Vigevano</city>
        <zip>27029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Fernando Fonseca</name>
      <address>
        <city>Amadora</city>
        <zip>P-2700</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
  </location_countries>
  <results_reference>
    <citation>Garufi C, Focan C, Tumolo S, et al.: Time finding study of chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L) and oxaliplatin (O) (chronoIFLO) against metastatic colorectal cancer: results from randomized EORTC 05011 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-2566, 2007.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

